CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 190 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $424,254 | -19.6% | 36,292 | -7.6% | 0.01% | -22.2% |
Q2 2023 | $527,789 | -18.9% | 39,270 | 0.0% | 0.01% | -18.2% |
Q1 2023 | $651,097 | +1.0% | 39,270 | +13.3% | 0.01% | -8.3% |
Q4 2022 | $644,602 | +46.5% | 34,656 | +1.1% | 0.01% | +33.3% |
Q3 2022 | $440,000 | -24.1% | 34,270 | -58.6% | 0.01% | -25.0% |
Q2 2022 | $580,000 | -15.5% | 82,770 | 0.0% | 0.01% | -20.0% |
Q1 2022 | $686,000 | -26.5% | 82,770 | -39.9% | 0.02% | -28.6% |
Q4 2021 | $933,000 | -47.9% | 137,770 | -59.2% | 0.02% | -43.2% |
Q3 2021 | $1,790,000 | -7.8% | 337,770 | 0.0% | 0.04% | -27.5% |
Q2 2021 | $1,942,000 | +24.7% | 337,770 | 0.0% | 0.05% | +37.8% |
Q1 2021 | $1,557,000 | +38.0% | 337,770 | 0.0% | 0.04% | +8.8% |
Q4 2020 | $1,128,000 | +12.5% | 337,770 | 0.0% | 0.03% | -43.3% |
Q3 2020 | $1,003,000 | -35.7% | 337,770 | 0.0% | 0.06% | -45.0% |
Q2 2020 | $1,560,000 | +20.0% | 337,770 | 0.0% | 0.11% | +101.9% |
Q1 2020 | $1,300,000 | – | 337,770 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |